175 related articles for article (PubMed ID: 32716969)
1. Cost-effectiveness of real-world administration of chemotherapy and add-on Viscum album L. therapy compared to chemotherapy in the treatment of stage IV NSCLC patients.
Thronicke A; Reinhold T; von Trott P; Grah C; Matthes B; Matthes H; Schad F
PLoS One; 2020; 15(7):e0236426. PubMed ID: 32716969
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Real-World Administration of Concomitant
Thronicke A; Reinhold T; von Trott P; Matthes H; Schad F
Evid Based Complement Alternat Med; 2020; 2020():3543568. PubMed ID: 32256640
[TBL] [Abstract][Full Text] [Related]
3. Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis.
Schad F; Thronicke A; Steele ML; Merkle A; Matthes B; Grah C; Matthes H
PLoS One; 2018; 13(8):e0203058. PubMed ID: 30148853
[TBL] [Abstract][Full Text] [Related]
4. Overall Survival of Nonmetastasized NSCLC Patients Treated With Add-On
Thronicke A; Matthes B; von Trott P; Schad F; Grah C
Integr Cancer Ther; 2020; 19():1534735420940384. PubMed ID: 32856476
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer.
Thongprasert S; Permsuwan U; Ruengorn C; Charoentum C; Chewaskulyong B
Asia Pac J Clin Oncol; 2011 Dec; 7(4):369-75. PubMed ID: 22151987
[TBL] [Abstract][Full Text] [Related]
8. Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer.
Axtner J; Steele M; Kröz M; Spahn G; Matthes H; Schad F
BMC Cancer; 2016 Aug; 16():579. PubMed ID: 27485618
[TBL] [Abstract][Full Text] [Related]
9. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer.
Wong KM; Ding K; Li S; Bradbury P; Tsao MS; Der SD; Shepherd FA; Chung C; Ng R; Seymour L; Leighl NB
Clin Lung Cancer; 2017 Jan; 18(1):e41-e47. PubMed ID: 27502323
[TBL] [Abstract][Full Text] [Related]
10. Carboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced non-small cell lung cancer and performance status 2.
Schluckebier L; Garay OU; Zukin M; Ferreira CG
Lung Cancer; 2015 Sep; 89(3):274-9. PubMed ID: 26143106
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.
Djalalov S; Beca J; Hoch JS; Krahn M; Tsao MS; Cutz JC; Leighl NB
J Clin Oncol; 2014 Apr; 32(10):1012-9. PubMed ID: 24567430
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
15. The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation.
Loveman E; Jones J; Hartwell D; Bird A; Harris P; Welch K; Clegg A
Health Technol Assess; 2010 Mar; 14(19):1-204. PubMed ID: 20356561
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.
Cromwell I; van der Hoek K; Malfair Taylor SC; Melosky B; Peacock S
Lung Cancer; 2012 Jun; 76(3):472-7. PubMed ID: 22226627
[TBL] [Abstract][Full Text] [Related]
18. Patients with Advanced or Metastasised Non-Small-Cell Lung Cancer with
Schad F; Thronicke A; Hofheinz RD; Matthes H; Grah C
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672690
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer.
Hillner BE; Smith TJ
Semin Oncol; 1996 Apr; 23(2 Suppl 5):25-30. PubMed ID: 8610234
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan.
Ahn MJ; Tsai CM; Hsia TC; Wright E; Chang JW; Kim HT; Kim JH; Kang JH; Kim SW; Bae EJ; Kang M; Lister J; Walzer S
Asia Pac J Clin Oncol; 2011 Jun; 7 Suppl 2():22-33. PubMed ID: 21585705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]